- Home
- CNTB vs CBUS Comparison
CNTB vs CBUS Comparison
Compare CNTB & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | CBUS |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 121.1M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNTB | CBUS |
|---|---|---|
| Price | $2.62 | $1.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.67 | ★ $9.00 |
| AVG Volume (30 Days) | 203.0K | ★ 411.8K |
| Earning Date | 08-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.33 |
| EPS | ★ N/A | N/A |
| Revenue | $64,000.00 | ★ $3,639,000.00 |
| Revenue This Year | N/A | $112.72 |
| Revenue Next Year | N/A | $83.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $1.09 |
| 52 Week High | $3.82 | $4.19 |
Technical Indicators
Market Signals| Indicator | CNTB | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 43.20 |
| Support Level | $2.31 | $1.43 |
| Resistance Level | $2.86 | $1.50 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 63.95 | 53.42 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.